Table 1—
RepaglinideGlibenclamideP
Numbers of hypoglycemic symptomatic events associated with glycemia <4.0 mmol/l33700.0004
Numbers of hypoglycemic symptomatic events associated with glycemia <3.3 mmol/l24530.0004
Numbers of hypoglycemic symptomatic events associated with glycemia <2.7 mmol/l1023<0.0001
A1C (% at the beginning of each treatment)7.64 ± 1.4a7.50 ± 1.4c
A1C (% at the end of each treatment)6.87 ± 1.1b7.14 ± 1.3d
ΔA1C (%)−0.77 ± 1.0−0.36 ± 0.90.008
FPG at the beginning of each treatment (mmol/l)7.64 ± 1.3a7.22 ± 1.3e
FPG at the end of each treatment (mmol/l)6.61 ± 1.1b7.25 ± 1.2f
ΔFPG (mmol/l)−1.03 ± 1.2+0.02 ± 1.2<0.0001
2-h plasma glucose at the beginning of each treatment (mmol/l)8.93 ± 1.2a8.72 ± 1.2g
2-h plasma glucose at the end of each treatment (mmol/l)7.98 ± 1.1b8.49 ± 1.1h
Δ2-h plasma glucose (mmol/l)−0.95 ± 1.3−0.23 ± 1.4*
  • Data are means ± SD unless otherwise indicated. a vs. b, P < 0.0001; c vs. d, P = 0.0005; e vs. f, P = 0.77; g vs. h, P = 0.11.

  • *

    * Carry-over and period effect detected; the analysis was thus restricted to the first period only (−0.44 mmol/l in favor of repaglinide [95% CI −1.0 to 0.11]; P = 0.10).